140 filings
8-K
AKBA
Akebia Therapeutics Inc.
16 Apr 24
Entry into a Material Definitive Agreement
7:33am
8-K
AKBA
Akebia Therapeutics Inc.
27 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
8:35pm
8-K
AKBA
Akebia Therapeutics Inc.
15 Mar 24
Departure of Directors or Certain Officers
4:05pm
8-K
AKBA
Akebia Therapeutics Inc.
14 Mar 24
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:18pm
8-K
AKBA
Akebia Therapeutics Inc.
13 Feb 24
Departure of Directors or Certain Officers
8:00am
8-K
mo8mmvwbzuhof8i9
30 Jan 24
Entry into a Material Definitive Agreement
8:05am
8-K
4p2le7cckuc7byk
8 Jan 24
Departure of Directors or Certain Officers
4:08pm
8-K
omhvaoorktyzc z3
8 Jan 24
Results of Operations and Financial Condition
8:02am
8-K
3b5b31q g9
18 Dec 23
Entry into a Material Definitive Agreement
4:07pm
8-K
kqk1zw7n cmn7
21 Nov 23
Other Events
5:07pm
8-K
sogk 3pefa2
8 Nov 23
Akebia Therapeutics Reports Third Quarter 2023 Financial Results
7:33am
8-K
9u14y4bgk1 g912
2 Nov 23
Entry into a Material Definitive Agreement
4:34pm
8-K
dvebafnv kqd2q
25 Oct 23
Akebia Receives FDA Acceptance of Resubmission to NDA of
4:06pm
8-K
2uhg ucplkqy4269a
12 Oct 23
Departure of Directors or Certain Officers
8:31am
8-K
r3wejliqodx9q6 gyyoc
26 Sep 23
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
4:47pm
8-K
x41rex3yy 0lmghq2
25 Aug 23
Akebia Therapeutics Reports Second Quarter 2023 Financial Results
8:14am
8-K
txotor5u
17 Aug 23
Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing
4:09pm
8-K
euvz5m qlui8k2xc
11 Aug 23
Akebia Therapeutics Provides Update on Form 10-Q Filing
7:35am
8-K
2j9sdfnphrr9080vtza
1 Aug 23
Departure of Directors or Certain Officers
4:05pm
8-K
lnt1tp mdzf1az0mbim
18 Jul 23
Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
7:47am